Accutar Biotechnology Inc. has received FDA clearance of its IND application for AC-0676 for the treatment of patients with relapsed/refractory B-cell malignancies.
Lung and pancreatic cancer cells usually become chemotherapy resistant; the alternative to target nonapoptotic pathways was hypothesized as an approach for treating these cancers. Researchers from Sun Yat-sen University and their collaborators focused on the activation of pyroptosis as a therapeutic alternative to treat these resistant tumor types.
Turbine Ltd. began the new year with a partnership with Cancer Research Horizons, the innovation arm of Cancer Research UK, which will put its Simulatedcell computational biology platform to work on the vexed question of how best to position CDC7 inhibitors in cancer.
Kanaph Therapeutics Inc. and Yungjin Pharmaceutical Co., Ltd. have presented tyrosine-protein phosphatase nonreceptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of immunological, cardiovascular, eye disorders, fibrosis, cancer, Noonan syndrome, LEOPARD syndrome and neurofibromatosis type 1.
Newave Pharmaceutical LLC. and Guangzhou Lupeng Pharmaceutical Co., Ltd. have identified isoquinolines acting as epidermal growth factor receptor (EGFR) (mutant) inhibitors reported to be useful for the treatment of cancer, inflammation and autoimmune disease.
Incyte Corp. has disclosed GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
Xinthera Inc. has divulged pyridinones acting as MAP kinase-activated protein kinase 2 (MAPKAPK2) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, fibrosis, metabolic diseases, inflammation and cardiovascular and cerebrovascular disorders.
Pliant Therapeutics Inc. has received FDA clearance of its IND application for PLN-101095, an oral, small-molecule, dual selective inhibitor of integrins αvβ8 and αvβ1.
Results from a French study of a cohort of individuals with the inherited rare disease Fanconi anemia shed light on how some people with this condition go on to develop secondary leukemia. Writing in the Feb. 2, 2023, issue of Cell Stem Cell, the authors also described some initial tests on cell lines in a mouse model of a drug that has potential to treat individuals with Fanconi anemia who progress to leukemia.
Chan Zuckerberg Biohub and Stanford University have identified cyclin-dependent kinase 19 (CDK19) inhibitors reported to be useful for the treatment of triple-negative breast cancer.
RSS
